MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from offering, net of c...
Stock-based compensation
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Net loss
Pharmala escrow deposit -other a...
Gain on change in fair value of ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Loss on change in fair value of derivative liability
-
-
0
0
Amortization of debt discounts
-
-
0
0
Loss (gain) on extinguishment of debt
-
-
0
0
Gain on change in fair value of convertible notes
-
-
281,932
-
Gain on forgiveness of accrued compensation
-
-
0
0
Net loss
-2,274,397
-2,061,958
-2,575,031
-2,288,034
Decrease (increase) in prepaid contracts
-
-
0
-
Gain on change in fair value of convertible notes
549,098
1,282
-
-
Increase in prepaid and other current assets
-
-
0
-
Interest expense paid through sale of common stock
0
131,479
-
-
Amortization of prepaid contracts
191,142
189,041
193,242
193,242
Non-cash financing cost
-
-
200,000
-
Interest expense paid through sale of common stock
-
-
22,521
-
Stock-based compensation
490,997
500,992
463,241
1,071,333
Change in operating lease right of use asset and lease liabilities
3,842
-1,132
-
-
Accounts receivable
10,241
-2,637
2,637
-
Pharmala escrow deposit -other assets
600,000
-
-
-
Inventory
-12,778
-11,722
159,790
-
Prepaid and other current assets
-
-
-
-32,324
Other assets
-3,687
26,154
-7,544
-
Decrease in operating lease right of use asset
-
-
1,107
639
Increase in other liabilities
-
-
-
6,695
Accounts payable and accrued expenses
443,607
-164,010
160,294
-95,612
Accrued compensation
-8,575
25,255
-451,695
-8,867
Deferred revenue
859
-735
735
-
Refund liability
477
1,874
-
-
Accrued interest
0
-39,829
35,479
1,108
Proceeds from note payable, related parties
-
-
0
0
Net cash used in operating activities
-2,294,922
-1,432,100
-2,368,023
-1,154,450
Payment on notes payable-Nonrelated Party
-
-
0
-
Proceeds from exercise of stock options
0
5,507
-
-
Payment on convertible note payable
405,953
-
0
-
Proceeds from offering, net of costs
1,860,000
-
0
-
Proceeds from sale of common stock
-
-
0
0
Payment on notes payable-Related Party
-
-
146,432
-
Proceeds from issuance convertible note payable, net
-
-
5,580,000
-
Net change in cash
-
-
3,065,545
-
Net cash provided by financing activities
1,454,047
5,507
5,433,568
0
Net change in cash
-840,875
-1,426,593
3,065,545
-1,154,450
Beginning of period
2,362,749
3,789,342
723,797
3,769,510
End of period
1,521,874
2,362,749
3,789,342
723,797
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from offering,
net of costs
$1,860,000
Net cash provided by
financing activities
$1,454,047
Canceled cashflow
$405,953
Net change in cash
-$840,875
(55.54%↑ Y/Y)
Canceled cashflow
$1,454,047
Stock-based compensation
$490,997
(-44.45%↓ Y/Y)
Accounts payable and
accrued expenses
$443,607
(149.95%↑ Y/Y)
Amortization of prepaid
contracts
$191,142
(-49.72%↓ Y/Y)
Inventory
-$12,778
Change in operating
lease right of use...
$3,842
Other assets
-$3,687
Deferred revenue
$859
Refund liability
$477
Payment on convertible
note payable
$405,953
Net cash used in
operating activities
-$2,294,922
(-21.34%↓ Y/Y)
Canceled cashflow
$1,147,389
Net loss
-$2,274,397
(39.86%↑ Y/Y)
Pharmala escrow deposit
-other assets
$600,000
Gain on change in fair
value of convertible...
$549,098
Accounts receivable
$10,241
Accrued compensation
-$8,575
(-101.94%↓ Y/Y)
Buy us a coffee
JUPITER NEUROSCIENCES, INC. (JUNS)
JUPITER NEUROSCIENCES, INC. (JUNS)